My Op Ed in Today's Washington Post: "The long-lasting effects of viruses — and the anti-vaccine movement. For some people, a viral infection can have devastating long-term effects." wapo.st/4qjFtWk

The latest from @scottgottliebmd.bsky.social:

It's a good and personal piece. Earlier in his adult life, Gottlieb had Hodgkins disease, almost certainly as a result of Epstein-Barr virus infection. (Happily, Hodgkins is usually quite treatable cancer, as it was for him.)

The long-lasting effects of viruses — and the anti-vaccine movement: Dr. @scottgottliebmd.bsky.social had cancer caused by EBV, and remind us that viruses can leave life-long harms and risks, and vaccines that prevent infections prevent those, too. @postopinions.bsky.social wapo.st/4qjFtWk

My Op Ed in Today's Washington Post: "The long-lasting effects of viruses — and the anti-vaccine movement. For some people, a viral infection can have devastating long-term effects." wapo.st/4qjFtWk

Predictably, anti-vaccine groups are leveraging HHS action to move most pediatric vaccines off the recommended schedule (and conform U.S. guidelines to Denmark) to pressure red state legislatures to eliminate vaccinations as part of school entrance requirements. www.statnews.com/2026/01/29/v...

It appears that the new dietary guidelines stopped short of strengthening the recommendation to reduce alcohol consumption and may have weakened it — a missed public health opportunity that should be revisited as these guidelines are refined and updated. www.nbcnews.com/news/amp/rcn...

This is a policy choice. As Dr. Gottlieb recently put the issue on CNBC: if we substantially reduce vaccination rates, "we're going to have to build new pediatric hospitals." www.youtube.com/watch?v=e8CJ...

Shifting many pediatric vaccines into the category of shared clinical decision-making means in many red states governors and legislators will be pressured to strip them from school-entry requirements. Vaccination rates could fall sharply with stark regional differences in protection against disease

Shifting many pediatric vaccines into the category of shared clinical decision-making means in many red states governors and legislators will be pressured to strip them from school-entry requirements. Vaccination rates could fall sharply with stark regional differences in protection against disease

My segment on CNBC today Gottlieb: ‘If We Go to the Danish Model and We Substantially Reduce Vaccination … We’re Going to Have to Build New Pediatric Hospitals’ grabien.com/story?id=562...

To foster disruptive innovation with the potential to change medical paradigms, NIH policies should channel more funding to unconventional ideas and the early-career investigators who are pursuing them, a theme that I take up in my forthcoming book, Miracle Century www.statnews.com/2025/12/18/n...

To foster disruptive innovation with the potential to change medical paradigms, NIH policies should channel more funding to unconventional ideas and the early-career investigators who are pursuing them, a theme that I take up in my forthcoming book, Miracle Century www.statnews.com/2025/12/18/n...

NBC News: ‘Whooping cough cases soar as vaccination rates drop: In an NBC News data investigation of 31 states, about 70% of counties and jurisdictions fell below the target vaccination rate needed for community protection.’ www.nbcnews.com/health/kids-...

Must-read for health care regulators, by former FDA head @scottgottliebmd.bsky.social, pointing out challenges of introducing AI in health care systems -> Approval, benefit assessment and reimbursement regulation need system-specific consideration and design in order to support productivity gains!

12 former commissioners of the FDA came together to write a Perspectives piece for the New England Journal of Medicine; raising our concerns about recent changes to vaccine approval policy at the FDA and its implications for patients and public health.

My article in the current issue of JAMA Health Forum: “How AI Will Help Solve Medicine’s Productivity Challenges.”

My segment on Face the Nation today on recent changes by CDC’s vaccine advisory committee to the pediatric schedule. www.cbsnews.com/video/scott-...

Dr. Gottlieb: FDA is systemically trying to dismantle components of the vaccine approval process cnb.cx/4pfHbrT with @scottgottliebmd.bsky.social @cnbc.com

If new proposals detailed in an FDA memo are put into place, experts told me it would mean the end of annual flu shots. And end of most vaccines for pregnant people. And maybe the end of updates to pneumonia vaccines. And more. www.cidrap.umn.edu/childhood-va...

12 former commissioners of the FDA came together to write a Perspectives piece for the New England Journal of Medicine; raising our concerns about recent changes to vaccine approval policy at the FDA and its implications for patients and public health.

Lena Sun at the Washington Post reports that this important team at CDC has been rehired.

These large national cohorts provided data that supported healthcare policymaking across the public and private sectors. They were some of the most important works that only CDC was able to perform - and execute well - as a nationally representative survey. www.statnews.com/2025/10/14/c...

"China has no scientific edge over the United States," @scottgottliebmd.bsky.social writes. "China has only a policy edge, which derives from its deliberate economic strategy."

My segment on @cnbc.com Squawk Box today on the shift in drug discovery to China, the threat that it poses to the U.S. biotechnology ecosystem, and policy steps that the U.S. FDA can take to level the playing field for early drug discovery.

My hit on @cnbc.com today on the new actions to address autism and the need to exercise more judgment and caution youtu.be/B7t9ryBoBfQ

Measles Death Shows How Virus Can Hide in the Brain for Years www.aol.com/articles/mea...

My appearance on #CNBC today about the #CDC’s #ACIP meeting on vaccines, which could bring action by HHS to remove the MMRV vaccine, eliminate the recommendation for Hep B in newborns, and narrow use of Covid vaccines.

My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+ We risk a return of communicable diseases in children. www.youtube.com/watch?v=00cI...

My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+ We risk a return of communicable diseases in children. www.youtube.com/watch?v=00cI...

My segment from Friday in @cnbc.com on vaccine policy youtu.be/J9FVvNR-n_E

I’ll be coming up on @SquawkCNBC at 6:30 to discuss vaccine safety and public health.

📅 Join us Sept. 19 for a conference on #FDA policy reforms aimed at reducing drug development costs and getting valuable new treatments to patients faster. Speakers: @scottgottliebmd.bsky.social, Janet Woodcock, Ken Drazan, Lowell Schiller & more ➡️Registration: schaeffer.usc.edu/event/reform...

My editorial in JAMA Health Forum: To support the academic research enterprise, we should pursue regulatory reforms that enable institutions to advance more of their discoveries to patients and, in doing so, capture more economic value of innovations they achieve jamanetwork.com/journals/jam...

CSL, a major manufacturer of flu vaccine, is spinning off its entire vaccine unit and cutting up to 15% of its staff. Influenza vaccine uptake is off by about 10% www.wsj.com/business/csl...

From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force insights.citeline.com/pink-sheet/a...

From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force insights.citeline.com/pink-sheet/a...

FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers insights.citeline.com/pink-sheet/a...

My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.

My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.

My segment today on cnbc.com on the CDC’s ACIP meeting.

My segment today on cnbc.com on the CDC’s ACIP meeting.

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com

My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com

My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress

My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress

My op-ed on the large shift of drug discovery moving to China and policy steps the U.S. can take to keep the innovation economy in America. "Five years ago, U.S. drug makers didn’t license any new drugs from China. By 2024, one-third came from Chinese biotech"

How to stop the shift of drug discovery from the U.S. to China www.statnews.com/2025/05/06/h... from @scottgottliebmd.bsky.social via @statnews.com